US Patent

US11884696 — Crystalline 19-nor C3,3-disubstituted C21-n-pyrazolyl steroid

Method of Use · Assigned to Sage Therapeutics Inc · Expires 2037-08-23 · 11y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a crystalline 19-nor C3,3-disubstituted C21-pyrazolyl steroid and methods of making and using it.

USPTO Abstract

This invention relates to a crystalline 19-nor C3,3-disubstituted C21-pyrazolyl steroid of Formula (I), and compositions thereof. Also disclosed herein are methods of making the same and methods of using the same.

Drugs covered by this patent

Zurzuvae (ZURANOLONE) · Biogen

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2552`	—	Zurzuvae
`U-2552`	—	Zurzuvae
`U-2552`	—	Zurzuvae

Patent Metadata

Patent number: US11884696
Jurisdiction: US
Classification: Method of Use
Expires: 2037-08-23
Drug substance claim: No
Drug product claim: No
Assignee: Sage Therapeutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.